Statin Therapy to Improve Atherosclerosis in HIV Patients
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
In HIV patients, statin therapy will attenuate plaque inflammation, thus, making plaques less
vulnerable, will deter plaque progression, and improve endothelial function. In addition to
known cholesterol-lowering and C-reactive protein lowering effects, immunomodulatory effects
of statins will lead to a shift from pro-inflammatory monocyte and T cell subsets to less
atherogenic subpopulations.